PGEN Stock: Precigen, Inc. Stock Price, Analysis & Insights
Get live pgen stock price $4.85, comprehensive Precigen, Inc. stock analysis, charts, news, and expert forecast. Real-time pgen stock data and investment insights.
Loading chart...
Company Overview
Precigen, Inc. discovers and develops the next generation of gene and cellular therapies in the United States. It also provides disease-modifying therapeutics; genetically engineered swine for regenerative medicine applications; and reproductive and embryo transfer technologies. In addition, the company offers UltraVector platform that incorporates advanced DNA construction technologies and computational models to design and assemble genetic components into complex gene expression programs; mbIL15, a gene that enhances functional characteristics of immune cells; Sleeping Beauty, a non-viral transposon/transposase system; AttSite recombinases, which breaks and rejoins DNA at specific sequences; AdenoVerse technology platform, a library of engineered adenovector serotypes; and L. lactis is a food-grade bacterium. Additionally, it provides RheoSwitch, an inducible gene switch system that provides quantitative dose-proportionate regulation of the amount and timing of target protein expression; kill switches to selectively eliminate cell therapies in vivo; tissue-specific promoters; UltraCAR-T platform for the treatment of cancer; AdenoVerse Immunotherapy, a library of proprietary adenovectors for the gene delivery; and ActoBiotics platform, genetically modified bacteria that deliver proteins and peptides at mucosal sites. Precigen, Inc. has collaboration and license agreements with Alaunos Therapeutics, Inc.; Ares Trading S.A.; Oragenics, Inc.; Castle Creek Biosciences, Inc.; Intrexon Energy Partners, LLC; and Intrexon Energy Partners II, LLC. The company was formerly known as Intrexon Corporation and changed its name to Precigen, Inc. in January 2020. Precigen, Inc. was founded in 1998 and is based in Germantown, Maryland.
Company Information
- CEO
- Helen Sabzevari MPH,
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 143
Contact Information
- Website
- https://www.precigen.com
- Address
- 20374 Seneca Meadows Parkway
- Country
- US
Investment Analysis & Business Insights
Investment Highlights
✓ Strong presence in the Healthcare sector with established market position
Business Model & Strategy
Precigen, Inc. operates in the Biotechnology industry, focusing on medical services, pharmaceutical development, and healthcare delivery. Under the leadership of CEO Helen Sabzevari MPH,, the company navigates Healthcare sector dynamics while pursuing growth opportunities. The Biotechnology model requires regulatory compliance, research investment, and patient outcomes to maintain competitiveness and drive shareholder value.
Market Position & Competitive Landscape
Precigen, Inc. competes in the Biotechnology within the broader Healthcare. With 1.5 billion in market capitalization, the company is positioned as a emerging competitor in its sector. The Healthcare is characterized by demographic shifts, regulatory changes, and medical breakthroughs. As a publicly traded company on the NASDAQ Global Select, Precigen, Inc. provides investors with liquidity and transparency while subject to regulatory oversight. Investors evaluating Precigen, Inc. should consider industry-specific trends, competitive positioning, and Healthcare sector fundamentals.
Important Investment Considerations
- ⚠All investments carry risk, including potential loss of principal for Precigen, Inc. shareholders
- ⚠Market volatility can significantly impact stock price, especially for smaller companies
- ⚠Sector-specific risks in Healthcare may affect company performance
- ⚠Past performance does not guarantee future results for Precigen, Inc.
- ⚠Investors should consider how Precigen, Inc. fits within their overall portfolio allocation
- ⚠Valuation metrics suggest potential, but require fundamental analysis
Market Cap
1.46B
P/E Ratio
-11.83
Beta
1.16
Investment Analysis & Insights
Key Investment Highlights
- Market Position: Healthcare leader with 1.46B market capitalization
- Trading Volume: 16.79M shares traded today
- Price Range: 52-week range of $0.65 - $5.23
- Exchange: Listed on NASDAQ Global Select
Financial Metrics
Market Analysis for Precigen, Inc.
Precigen, Inc. (PGEN) operates in the Biotechnology industry within the Healthcare sector. With a current market capitalization of 1.46B, the company represents a significant player in its market. The stock is currently trading at $4.85 with a positivedaily change of 25.65%.
The company's 143 employee base and presence on the NASDAQ Global Selectexchange position it as a Healthcare sector leader. Investors should consider the stock's P/E ratio of -11.83, beta of 1.16, and 52-week price range from $0.65 to $5.23when evaluating investment opportunities.
Why Invest in Precigen, Inc.?
Strengths
- • Established market presence in Healthcare
- • Strong financial metrics and market position
- • Listed on major exchange (NASDAQ Global Select)
- • Experienced leadership under Helen Sabzevari MPH,
Investment Considerations
- • Monitor sector-specific market trends
- • Track quarterly earnings performance
- • Consider market volatility and beta
- • Evaluate long-term growth potential
Related Healthcare Stocks
About Healthcare Sector
The Healthcare sector includes companies that provide medical services, develop pharmaceuticals, manufacture medical devices, and offer health insurance.